Ginkgo Bioworks Holdings, Inc. WT Fundamental Analysis
Ginkgo Bioworks Holdings, Inc. WT (DNA-WT) shows weak financial fundamentals with a PE ratio of -1.55, profit margin of -2.15%, and ROE of -57.31%. The company generates $163.9B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -253.4/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze DNA-WT's fundamental strength across five key dimensions:
Efficiency Score
WeakDNA-WT struggles to generate sufficient returns from assets.
Valuation Score
ExcellentDNA-WT trades at attractive valuation levels.
Growth Score
WeakDNA-WT faces weak or negative growth trends.
Financial Health Score
ExcellentDNA-WT maintains a strong and stable balance sheet.
Profitability Score
WeakDNA-WT struggles to sustain strong margins.
Key Financial Metrics
Is DNA-WT Expensive or Cheap?
P/E Ratio
DNA-WT trades at -1.55 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, DNA-WT's PEG of -0.03 indicates potential undervaluation.
Price to Book
The market values Ginkgo Bioworks Holdings, Inc. WT at 1.07 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -1.22 times EBITDA. This is generally considered low.
How Well Does DNA-WT Make Money?
Net Profit Margin
For every $100 in sales, Ginkgo Bioworks Holdings, Inc. WT keeps $-2.15 as profit after all expenses.
Operating Margin
Core operations generate -2.11 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-57.31 in profit for every $100 of shareholder equity.
ROA
Ginkgo Bioworks Holdings, Inc. WT generates $-29.46 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Ginkgo Bioworks Holdings, Inc. WT generates limited operating cash flow of $-192.47B, signaling weaker underlying cash strength.
Free Cash Flow
Ginkgo Bioworks Holdings, Inc. WT generates weak or negative free cash flow of $-212.52B, restricting financial flexibility.
FCF Per Share
Each share generates $-3.08 in free cash annually.
FCF Yield
DNA-WT converts -35.33% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-1.55
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.03
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.07
vs 25 benchmark
P/S Ratio
Price to sales ratio
3.67
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.93
vs 25 benchmark
Current Ratio
Current assets to current liabilities
5.15
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.57
vs 25 benchmark
ROA
Return on assets percentage
-0.29
vs 25 benchmark
ROCE
Return on capital employed
-0.31
vs 25 benchmark
How DNA-WT Stacks Against Its Sector Peers
| Metric | DNA-WT Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -1.55 | 34.27 | Better (Cheaper) |
| ROE | -57.31% | 377.00% | Weak |
| Net Margin | -215.41% | -42945.00% (disorted) | Weak |
| Debt/Equity | 0.93 | 0.78 | Neutral |
| Current Ratio | 5.15 | 5.54 | Strong Liquidity |
| ROA | -29.46% | -162.00% (disorted) | Weak |
DNA-WT outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Ginkgo Bioworks Holdings, Inc. WT's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation